UBS Asset Management Americas Inc. lessened its stake in shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) by 1.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 183,997 shares of the company’s stock after selling 2,793 shares during the quarter. UBS Asset Management Americas Inc. owned approximately 0.70% of Reata Pharmaceuticals worth $5,211,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nationwide Fund Advisors lifted its holdings in shares of Reata Pharmaceuticals by 38.1% during the 2nd quarter. Nationwide Fund Advisors now owns 4,368 shares of the company’s stock valued at $138,000 after purchasing an additional 1,206 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Reata Pharmaceuticals by 37.4% during the 2nd quarter. Wells Fargo & Company MN now owns 5,591 shares of the company’s stock valued at $176,000 after purchasing an additional 1,521 shares during the last quarter. First Allied Advisory Services Inc. purchased a new stake in shares of Reata Pharmaceuticals during the 3rd quarter valued at $203,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Reata Pharmaceuticals by 102.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 7,343 shares of the company’s stock valued at $233,000 after purchasing an additional 3,715 shares during the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Reata Pharmaceuticals by 42.5% during the 3rd quarter. American International Group Inc. now owns 7,528 shares of the company’s stock valued at $234,000 after purchasing an additional 2,247 shares during the last quarter. 49.33% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently commented on RETA shares. Cowen reiterated a “buy” rating on shares of Reata Pharmaceuticals in a report on Tuesday, November 14th. BidaskClub lowered Reata Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 23rd. Finally, Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. Three equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. Reata Pharmaceuticals has an average rating of “Hold” and an average target price of $54.71.
Reata Pharmaceuticals (NASDAQ:RETA) last issued its earnings results on Friday, March 2nd. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.08). The company had revenue of $9.96 million during the quarter, compared to the consensus estimate of $11.18 million. research analysts anticipate that Reata Pharmaceuticals Inc will post -2.54 EPS for the current fiscal year.
In other news, Director Cpmg Inc bought 200,000 shares of Reata Pharmaceuticals stock in a transaction that occurred on Thursday, December 14th. The stock was bought at an average price of $24.79 per share, for a total transaction of $4,958,000.00. Following the purchase, the director now directly owns 113 shares of the company’s stock, valued at approximately $2,801.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director R Kent Mcgaughy, Jr. bought 17,000 shares of Reata Pharmaceuticals stock in a transaction that occurred on Friday, December 29th. The stock was purchased at an average price of $28.47 per share, with a total value of $483,990.00. Following the purchase, the director now directly owns 113 shares in the company, valued at $3,217.11. The disclosure for this purchase can be found here. Insiders purchased a total of 409,925 shares of company stock valued at $10,359,964 in the last 90 days. 44.00% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/12/ubs-asset-management-americas-inc-sells-2793-shares-of-reata-pharmaceuticals-inc-reta.html.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.